Orlando, FL -- (SBWIRE) -- 10/10/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Sarepta Therapeutics Inc (NASDAQ:SRPT), VIVUS, Inc.(NASDAQ:VVUS).
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares declined 11.25% to $44.42. Deutsche Bank restated their fair value rating on shares of SRPT in a report released on Oct. 9. Deutsche Bank currently has a $213.00 price objective on the stock. Separately, Deutsche Bank upgraded shares of Sarepta Therapeutic from a hold rating to a buy rating in a report released on Sept. 24. Deutsche Bank currently has $71.00 price objective on the stock, up from their previous price objective of $45.00.
Additionally, SRPT’s Director M Kathleen Behrens purchased 6,500 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were purchased at an average price of $37.04 per share, for a total transaction of $240,760.00. Following the completion of the transaction, the director now directly owns 44,166 shares in the company.
Are investors worried about the recent updates with SRPT? Find out with a free trend analysis HERE
VIVUS, Inc.(NASDAQ:VVUS) shares dropped 0.10% to $10.12. The company on Oct. 9 announced new data published online in Diabetes Care demonstrating the effects of Qsymia (phentermine and topiramate extended-release) capsules CIV, on the progression to type 2 diabetes. In the study, high-risk overweight or obese patients with prediabetes and/or metabolic syndrome who were taking Qsymia over a two year period experienced reductions of up to 78.7% in the annualized incidence rate of type 2 diabetes, in addition to losing weight. The American Association of Clinical Endocrinologists recognizes obesity and prediabetes as significant risk factors for progression to diabetes and associated complications.
Additionally, VVUS‘s stock had its “buy” rating reaffirmed by stock analysts at Bank of America Corp. in a report issued on Oct. 2. They currently have a $17.00 price target on the stock.
Is VVUS going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)